about
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemiaDiagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetEarly prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura.Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study.Long-term management of chronic immune thrombocytopenic purpura in adults.Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.A novel approach to the evaluation of bleeding-related episodes in patients with chronic immune thrombocytopenia.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara studyCharacteristics and management of primary and other immune thrombocytopenias: Spanish registry study.Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone.[Chronic idiopathic thrombocytopenic purpura in adults. Clinico-biological profile and therapeutic response][Clinical profile and course of paroxysmal nocturnal hemoglobinuria]DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia.Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature.Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.Bone marrow-derived cells from male donors do not contribute to the endometrial side population of the recipientMolecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosisCost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.The European LeukemiaNet: achievements and perspectives.A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysisDown-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemiaCYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
P50
Q27022521-EDF48293-E410-4ED0-BC52-43B1C3830E5BQ29012757-A6F65314-808B-4DF7-B49E-A531FCEDDAECQ33331150-0262FA41-DB81-44B6-8E51-7885AB432E4EQ33338940-C604D706-D493-4914-BEBB-50C9B18D7B98Q33357478-6DE7B2BF-1E8C-4CA4-B11A-1DF3102151CDQ33377454-9715ADD4-9AC2-4813-A3F4-7AB9D21C41CAQ33378523-FE159256-BF65-431C-B797-46EB01E991F7Q33381983-881649BC-B61D-4568-B9D9-07D3777B8EFAQ33389149-505F68A0-4FDD-4851-A25B-34924A06C2C1Q33392225-C6C60C0B-D6C1-4CC0-A06E-9EA0381B61F5Q33392610-0AE60A1A-790D-4F45-B907-96973FD90783Q33393541-C3D9D3C0-4165-43AD-99B6-91ED4005AD11Q33397101-616F39A4-5F35-4D28-9D60-52A91C94717FQ33400700-B61A00FC-7686-4ACD-ACA3-52C3C7C278BFQ33424306-0BAD7685-A5E2-4C7B-9EFD-D8EBE8C9A36EQ33441053-4ACC1DFB-ABE0-49F3-B21D-67647CAF1DA4Q33441706-48B4DC69-96ED-4EB9-AA80-E8C510CF213EQ33442326-602EAC67-8F34-4A48-957A-361DDE4FE080Q33442358-AD994DCA-F36D-4EC7-A287-1C411F54B0A8Q33457996-CDDE9FD3-B408-4BB2-A861-6F8FD0C930FAQ33482619-905BFAE5-F63C-4479-ABC0-13247206455BQ33493090-EB9817BC-BC87-4E34-9E1A-8AA80874863BQ33680945-40F94998-2FFC-496D-8748-A2B5EC557E73Q33707423-F0134174-3668-4848-A2EE-F43FA427EE62Q33727686-34E1649D-C13C-4FEE-BF58-71C947E8070EQ33800102-7F7B6968-9262-49B7-955B-0A5A2ED42F8EQ33827846-DAAE79EC-AE8A-4211-AA3F-F7CFE577DA58Q33978951-F2816389-FDA4-44AE-9090-C06826F3F8F0Q34088767-2EE5995D-1603-40DC-9FE8-0C4950C6E9F7Q34140424-D6B95EC9-02C5-455F-968A-5EA63641E157Q34198047-E5ECBD1E-6822-44FB-B834-27772DA79CE0Q34218399-1DD52FF9-D31A-4B98-ADC0-A4D073411B61Q34451619-57EAD080-989C-450B-A6E2-238A95A9FC5DQ34505708-0CC2A901-C014-4644-B07F-EB997DE3806AQ34522736-936413B0-46F9-43B3-B718-FEA1347DC530Q34584443-726120EE-E1B7-4B4E-9FC3-16F0CD3C1E80Q35236079-0DE759E2-C699-47D4-A2A1-BC099664FF0EQ35265855-ECC7A6E0-CB16-4A6A-9EA4-969DDA75A1A1Q35266066-2CE61174-F5F9-4D64-AEF6-7C28198C9FEBQ35571053-D2815A12-EF8E-4FC1-8F63-FDE17D183A86
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Miguel A Sanz
@ast
Miguel A Sanz
@en
Miguel A Sanz
@es
Miguel A Sanz
@nl
Miguel A Sanz
@sl
type
label
Miguel A Sanz
@ast
Miguel A Sanz
@en
Miguel A Sanz
@es
Miguel A Sanz
@nl
Miguel A Sanz
@sl
prefLabel
Miguel A Sanz
@ast
Miguel A Sanz
@en
Miguel A Sanz
@es
Miguel A Sanz
@nl
Miguel A Sanz
@sl
P214
P244
P106
P21
P214
P244
n2018186601
P31
P496
0000-0003-1489-1177
P735
P7859
lccn-n2018186601